rfxcel Serialization Software: Is Your Serialization Data a Liability?

Overview: How rfxcel’s Serialization & Traceability Platform Transforms Pharmaceutical Supply Chains

rfxcel Serialization Software is a pharmaceutical serialization and traceability platform that generates, assigns and validates unique product identifiers to support tracking across the medicine supply chain. It addresses a practical bottleneck: duplicate serial numbers, inconsistent formats and incorrect packaging data can undermine traceability when exchanged between connected systems and trading partners. Its emphasis is on maintaining reliable product records before errors propagate downstream.

The platform combines configurable serial-number generation with automated checks for duplicates, number formats, packaging levels and previously allocated identifiers. Scanning integration captures barcode data and recognises whether it relates to a product, case or pallet, while a central repository retains serialized-item and event histories. The documented capabilities centre on data processing and validation; the cited materials do not establish machine learning or AI as the underlying mechanism.

Operationally, these capabilities can reduce manual data checking and the reconciliation work associated with inconsistent records. Connecting serialization data with existing technologies and trading partners also supports more consistent information exchange. The potential value is fewer avoidable data errors and a more dependable record for investigating product movements, although the cited pages do not quantify time savings or demonstrate direct clinical outcomes.

Last checked on October 22, 2026: rfxcel remains active under Antares Vision Group, whose acquisition by Crane NXT was announced as completed on April 1, 2026.

What is rfxcel Serialization Software?

rfxcel Serialization Software generates, assigns and validates pharmaceutical product serial numbers to support serialization, traceability and data exchange across life-sciences supply chains. Designed for pharmaceutical companies and their supply-chain partners, it integrates with existing systems and scanners and maintains auditable histories of serialized items and events. Its documented technical approach includes duplicate-number detection, format and packaging-level checks, and single-tenant cloud hosting; the cited product pages do not specify AI or machine-learning functionality.

Intended Use and Limitations

• ISO/IEC 27001: Antares Vision Group announced information-security management certification through rfxcel’s San Ramon location in July 2023; current certificate validity and scope require verification.

• rfxcel’s existing ISO 9001 quality-management certification was reported in the same announcement; this is an organisational credential, not certification of clinical effectiveness.

• FDA-published DSCSA pilot materials document rfxcel’s participation in testing authorised-trading-partner identity verification with SAP, Spherity, Legisym and HDA; participation does not constitute FDA product approval.

• Integration with Spherity’s CARO credentialing service supports verification of trading partners’ identities and licensing, authenticated product-verification messages and auditable interactions within rfxcel-enabled DSCSA solutions.

• LedgerDomain documents rfxcel VRS integration for authorised-trading-partner credentials and reports completed credential-integration testing through the HDA VRS Working Group.

• rfxcel documents support for GS1, EPCIS, EDI and API-based exchange of serialized pharmaceutical data, providing an interoperability basis that buyers should validate against their own systems.

• Antares Vision Group acquired rfxcel in 2021, placing the business within a broader inspection and traceability technology portfolio.

• Crane NXT completed its acquisition of Antares Vision on April 1, 2026, making Antares Vision a wholly owned subsidiary and changing rfxcel’s ultimate ownership.